Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Abeona Therapeutics (ABEO) over the last 11 years, with Sep 2025 value amounting to $6.9 million.

  • Abeona Therapeutics' Accumulated Expenses rose 32.21% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 32.21%. This contributed to the annual value of $6.3 million for FY2024, which is 5.81% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Accumulated Expenses is $6.9 million, which was up 25.35% from $5.5 million recorded in Q2 2025.
  • Abeona Therapeutics' Accumulated Expenses' 5-year high stood at $6.9 million during Q3 2025, with a 5-year trough of $2.2 million in Q2 2021.
  • In the last 3 years, Abeona Therapeutics' Accumulated Expenses had a median value of $4.9 million in 2024 and averaged $4.7 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Accumulated Expenses tumbled by 40.89% in 2021, and later surged by 143.42% in 2022.
  • Over the past 5 years, Abeona Therapeutics' Accumulated Expenses (Quarterly) stood at $5.6 million in 2021, then dropped by 28.54% to $4.0 million in 2022, then soared by 49.96% to $6.0 million in 2023, then rose by 5.81% to $6.3 million in 2024, then surged by 32.21% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $5.5 million for Q2 2025, and $3.9 million during Q1 2025.